Morning Glory – Ipomoea

by | Dec 19, 2023 | Morning Glory

How Can We Help?
You are here:
< Back

Lerisetron (code name F-0930-RS) is a drug which acts as an antagonist at the 5-HT3 receptor.[1] It is a potent antiemetic[2][3] and was in clinical trials for the treatment of nausea associated with cancer chemotherapy.[4]

See also

References

  1. ^ Orjales A, Mosquera R, Labeaga L, Rodes R (February 1997). "New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation". Journal of Medicinal Chemistry. 40 (4): 586–93. doi:10.1021/jm960442e. PMID 9046349.
  2. ^ Gomez-de-Segura IA, Grande AG, De Miguel E (1998). "Antiemetic effects of Lerisetron in radiation-induced emesis in the dog". Acta Oncologica. 37 (7–8): 759–63. doi:10.1080/028418698430160. PMID 10050999.
  3. ^ Cooper M, Sologuren A, Valiente R, Smith J (2002). "Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers". Arzneimittel-Forschung. 52 (9): 689–94. doi:10.1055/s-0031-1299952. PMID 12404884. S2CID 24423582.
  4. ^ Huckle R (July 2003). "Lerisetron. FAES". Current Opinion in Investigational Drugs. 4 (7): 874–7. PMID 14619411.
Categories
Table of Contents